InMed to Participate at Virtual Conferences in January 2021

Rhea-AI Summary

InMed Pharmaceuticals (NASDAQ: INM) will participate in several virtual investor and partnering conferences in January 2021. Key events include the H.C. Wainwright BioConnect Conference from January 11-14, where a presentation by CEO Eric A. Adams will be available on demand. Additionally, the BIO Partnering at JPM will occur January 11-15, with registration options available. The Edison Open House: Global Healthcare 2021 is set for January 26-28. InMed focuses on developing cannabinoid-based medications for diseases with significant unmet medical needs.

VANCOUVER, BC, Jan. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that InMed will be participating in the following virtual investor and partnering conferences in January 2021. 

H.C. Wainwright BioConnect Conference
Date: January 11-14^th
Presentation Details: The company presentation by Eric A. Adams, President and CEO of InMed, will be available on demand beginning January 11^th at 6am EST and can be found at the below link. The presentation will be archived for 90 days following the conclusion of the event.
Presentation Link: https://journey.ct.events/view/a48c3f9e-1802-4279-95ca-eff84fafe024

BIO Partnering at JPM
Date: January 11-15^th
Registration Link: https://www.bio.org/events/bio-partnering-jpm/registration 
To request a 1x1 meeting, please reach out to info@inmedpharma.com. 

Edison Open House: Global Healthcare 2021
Date: January 26-28^th
Presentation information will be made available closer to the event. To register for the event and request a 1x1 meeting, please reach out to lyonker@edisongroup.com.

Information on each event, as well as links to presentations as they become available, will be posted on InMed's event page, which can be found at: https://journey.ct.events/view/a48c3f9e-1802-4279-95ca-eff84fafe024.

About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol ("CBN") in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: participating in multiple conferences in January 2021, including the H.C. Wainwright BioConnect 2021 Conference, BIO Partnering at JPM 2021, and Edison Open House Global Healthcare 2021; leading the way in the clinical development of cannabinol (CBN); developing a pipeline of cannabinoid-based medications in diseases with high unmet medical need; and delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

View original content:http://www.prnewswire.com/news-releases/inmed-to-participate-at-virtual-conferences-in-january-2021-301201470.html

SOURCE InMed Pharmaceuticals Inc.

FAQ

What are the key dates for InMed's participation in January 2021 conferences?

InMed will participate in the H.C. Wainwright BioConnect Conference from January 11-14, the BIO Partnering at JPM from January 11-15, and the Edison Open House: Global Healthcare 2021 from January 26-28.

Where can I find the presentation from InMed's participation at the H.C. Wainwright BioConnect Conference?

The presentation will be available on demand starting January 11 at 6am EST and will be archived for 90 days. You can access it through their official presentation link.

What is InMed Pharmaceuticals' focus in their drug development?

InMed Pharmaceuticals is developing cannabinoid-based medications, particularly focusing on the therapeutic benefits of cannabinol (CBN) for diseases with high unmet medical needs.

How can I register for the BIO Partnering at JPM event?

You can register for the BIO Partnering at JPM event through their official registration link, which is provided in the press release.

What is the main goal of InMed Pharmaceuticals as stated in the press release?

The main goal of InMed Pharmaceuticals is to deliver new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.